P&T News: March 1997: The Recommended Childhood Vaccination Schedule: Update on Recent Changes

Table 2: Vaccine Dosing and Administration Guidelines for Currently Marketed Products

Joan M. Murhammer, R.Ph., Clinical Pharmacist
Peer Review Status: Internally Peer Reviewed by Ellen A. Link, M.D., Clinical Assistant Professor, Department of Pediatrics and Jody R. Murph, M.D., Associate Professor, Department of Pediatrics


Vaccination

Brand Name/Formulary Status(2)

Dose

Route

Age Range

Recommended
Frequency

Hepatitis B

Engerix[R]-B

10 mcg/0.5 ml

IM

0 to 9 yrs

0, 1, 6 mos

20 mcg/ 1 ml

IM

20 or more yrs

0, 1, 6 mos

Recombivax[R]HB

2.5 mcg/0.5 ml

IM

0 to 10 yrs

HBsAG(-) mother; 0, 1, 6 mos starting at birth or 2 mos

5 mcg/0.5 ml

IM

0 to 10 yrs

HBsAG(+) mother; 0, 1, 6 mos starting at birth or 2 mos

5 mcg/0.5 ml

IM

11 to 19 yrs

0, 1, 6 mos

10 mcg/1 ml

IM

20 or more yrs

0, 1, 6 mos

Diphtheria, Tetanus, & Acellular Pertussis

Infanrix[R], Acel-Imune[R], Tripedia[R]

0.5 ml

IM

6 wks up to 7 yrs

2,4,6,15 to 18 mos, and 4 to 6 yrs (5 doses)

Diphtheria, Tetanus, & Pertussis

Connaught

0.5 ml

IM

6 wks up to 7 yrs

2,4,6,15 to 18 mos, and 4 to 6 yrs (5 doses)

Haemophilus B Conjugate (Hib)(4)

HibTITER[R] (HbOC), ActHIB[R]/OmniHIB[R] (PRP-T)

0.5 ml

IM

6 wks up to 5 yrs

2,4,6,12 to 15 mos (4 doses)

Pedvax[R] HIB (PRP-OMP)

0.5 ml

IM

6 wks up to 5 yrs

2,4,12 to 15 mos (3 doses)

ProHIBIT[R] (PRP-D)

0.5 ml

IM

18 mos to 5 yrs

Only approved for use as a booster dose

Polio(5)

Orimune[R]

0.5 ml

PO

6 or more wks

2,4,6 to 18 mos, and 4 to 6 yrs (4 doses) OR 2 doses at 12 to 18 mos and 4 to 6 yrs after receiving 2 doses of IPV at 2 and 4 mos

IPOL[R], Poliovax[R]

0.5 ml

SQ

6 or more wks

2,4,12 to 18 mos and 4 to 6 yrs (4 doses) OR 2 doses at 2 and 4 mos followed by 2 doses of OPV at 12 to 18 mos and 4 to 6 yrs

Measles, Mumps, and & Rubella

M-M-R II[R]

0.5 ml

SQ

12 or more mos

12 to 15 mos and either 4 to 6 yrs or 11 to 12 yrs (2 doses)

Varicella

Varivax[R]

0.5 ml

SQ

12 or more mos

12 to 18 mos (1 dose) If not given at 12 to 18 mos, 1 dose for ages 1 to 12 yrs and 2 doses given 4 to 8 wks apart if 13 yrs or older

Hepatitis A

Havrix[R]

360 EL.U/0.5ml[6]

IM

2 to 18 yrs

0,1,6 to 12 mos (3 doses)

720 EL.U/0.5ml[6]

IM

2 to 18 yrs

0,6 to 12 mos (2 doses)

1440 EL.U/1 ml

IM

more than 18 yrs

0,6 to 12 mos (2 doses)

Vaqta[R]

25 U/0.5 ml

IM

2 to 17 yrs

0,6 to 18 mos (2 doses)

50 U/1 ml

IM

more than 17 yrs

0,6 mos (2 doses)

Hepatitis B & Haemophilus b Conjugate (PRP-OMP)(7)

Comvax[R]

0.5 ml

IM

6 or more wks

2,4,12 to 15 mos (3 doses)

Diphtheria, Tetanus, Pertussis, & Haemophilus b Conjugate (HbOC)

Tetramune[R]

0.5 ml

IM

6 wks up to 7 yrs

2,4,6 and 15 to 18 mos (4 doses) and an additional dose of DTP/DTaP needs to be administered at 4 to 6 yrs

Diphtheria, Tetanus, Acellular Pertussis, & Haemophilus b Conjugate (PRP-T)

TriHIBIT[R]

0.5 ml

IM

15 mos to 5 yrs

15 to 18 mos (not approved for the primary 3 doses) and an additional dose of DTP/DTaP needs to be administered at 4 to 6 yrs

1. These are general administration guidelines for children who start the vaccine schedule at the appropriate age. See the 1994 Red Book for guidelines on accelerated schedules and for contraindications and precautions to the agents' uses.

2. Bold print designates vaccines available on the UIHC Formulary.

3. DTaP is the preferred agent for all doses in the pertussis series.

4. The number of doses required depends on the age of the patient and the product used.

5. Sequential IPV/OPV is the preferred regimen.

6. Those who receive an initial dose of 360 EL.U or 720 EL. U should continue on that dosing schedule. Individuals should not alternate between the two strengths. Please note, the 360 EL.U strength is not currently available on the UIHC Formulary.

7. Babies born to HBsAG(+) mothers may receive 3 doses of Comvax[R], but require hepatitis B vaccine and hepatitis B immune globulin at birth.

Title Page